公开(公告)号：US11466094B2

公开(公告)日：2022-10-11

申请号：US15813657

申请日：2017-11-15

Applicant: Genentech, Inc.

Inventor： Yu-Waye Chu ,  Iraj Hosseini ,  Saroja Ramanujan ,  Kapil Gadkar ,  Chi-Chung Li

IPC: A61K31/573 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00

Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20230242659A1

公开(公告)日：2023-08-03

申请号：US18173417

申请日：2023-02-23

Applicant: Genentech, Inc.

Inventor： Yu-Waye Chu ,  Iraj Hosseini ,  Saroja Ramanujan ,  Kapil Gadkar ,  Chi-Chung Li

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/573

CPC classification number: C07K16/2887 ,  C07K16/2809 ,  C07K16/2827 ,  A61K39/3955 ,  C07K16/2866 ,  A61K31/573 ,  C07K2317/41 ,  C07K2317/24 ,  A61K2039/545

Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20240376223A1

公开(公告)日：2024-11-14

申请号：US18785404

申请日：2024-07-26

Applicant: Genentech, Inc.

Inventor： Yu-Waye Chu ,  Iraj Hosseini ,  Saroja Ramanujan ,  Kapil Gadkar ,  Chi-Chung Li

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/00 ,  A61K39/395

Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20230190932A1

公开(公告)日：2023-06-22

申请号：US18050736

申请日：2022-10-28

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Catherine GRANIER ,  Andrea Knapp ,  Chi-Chung Li ,  Carol Elaine O'Hear ,  Enkhtsetseg Purev ,  Michael C. Wei

IPC: A61K39/395 ,  A61K31/454 ,  A61P35/00 ,  A61P7/00

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61P35/00 ,  A61P7/00 ,  A61K2039/545

Abstract: The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having R/R FL by administering a combination of mosunetuzumab and lenalidomide.